CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-21 | Dowden Nathan J Chief Operating Officer | Sale | −3,275 | $15.13 | $50K | 65,373 |
| 2022-09-15 | Doshi Dipal President and CEO | Sale | −200 | $15.04 | $3K | 219,847 |
| 2022-09-15 | Dowden Nathan J Chief Operating Officer | Sale | −100 | $15.01 | $2K | 68,648 |
| 2022-09-15 | KREHER NERISSA Chief Medical Officer | Option exercise | +106 | $2.10 | $223 | 20,822 |
| 2022-09-15 | KREHER NERISSA Chief Medical Officer | Sale | −106 | $15.01 | $2K | 20,716 |
| 2022-09-15 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −106 | 28,905 | ||
| 2022-09-09 | Doshi Dipal President and CEO | Sale | −688 | $15.07 | $10K | 220,047 |
| 2022-09-09 | KREHER NERISSA Chief Medical Officer | Option exercise | +800 | $2.10 | $2K | 21,516 |
| 2022-09-09 | KREHER NERISSA Chief Medical Officer | Sale | −800 | $15.07 | $12K | 20,716 |
| 2022-09-09 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −800 | 29,011 | ||
| 2022-09-09 | Dowden Nathan J Chief Operating Officer | Sale | −865 | $15.06 | $13K | 68,748 |
| 2022-09-08 | Doshi Dipal President and CEO | Sale | −1,100 | $15.16 | $17K | 220,735 |
| 2022-09-08 | KREHER NERISSA Chief Medical Officer | Option exercise | +1,221 | $2.10 | $3K | 21,937 |
| 2022-09-08 | KREHER NERISSA Chief Medical Officer | Sale | −1,221 | $15.13 | $18K | 20,716 |
| 2022-09-08 | KREHER NERISSA Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −1,221 | 29,811 | ||
| 2022-09-08 | Dowden Nathan J Chief Operating Officer | Sale | −912 | $15.15 | $14K | 69,613 |
| 2022-09-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award | +5,503 | 16,489 | ||
| 2022-09-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award | +5,794 | 162,144 | ||
| 2022-09-01 | KREHER NERISSA Chief Medical Officer | Grant or award | +5,172 | 20,716 | ||
| 2022-09-01 | Dowden Nathan J Chief Operating Officer | Grant or award | +5,632 | 70,525 |
Page 22 of 26 · 517 trades